Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2017, Article ID 1658473, 7 pages
https://doi.org/10.1155/2017/1658473
Case Report

SLE and Non-Hodgkin’s Lymphoma: A Case Series and Review of the Literature

1Department of Internal Medicine, Advocate Illinois Masonic Medical Center, 836 W. Wellington Avenue, Chicago, IL 60657, USA
2Department of Rheumatology, Rush University Medical Center, 1725 West Harrison Street, Chicago, IL 60612, USA

Correspondence should be addressed to Abdul S. Mohammed; moc.liamg@namlasludbam

Received 9 December 2016; Accepted 16 March 2017; Published 27 March 2017

Academic Editor: Ruben Burgos-Vargas

Copyright © 2017 Prajwal Boddu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder punctuated by varied multiorgan complications all along the course of its natural history. Lymphoma represents a relatively well-recognized malignant phenomenon associated with lupus. The cause and effect relationships of lymphoma in SLE have been subject to extensive scrutiny with several studies reporting on clinic-pathologic characteristics and risk factors predicting lymphoma development in SLE. However, the pathogenic role of immunosuppressives in SLE-related lymphoma still remains unclear, and indices to help guide diagnosis, prognostication, therapy, and posttreatment monitoring are yet to be established. In this review, we describe 3 SLE patients who developed non-Hodgkin’s lymphoma at different time points of their disease. Through a careful dissection of the aforementioned cases, we intend to apprise readers of the currently available literature surrounding risk factors, management, and prognosis in SLE-related lymphoma. We will also review and discuss the implications of immunosuppressives in SLE-related lymphoma and the role of mycophenolate mofetil in SLE-related primary CNS lymphoma development.